Table 2.
Demographic, Clinical Characteristics and Outcomes of 69 Patients with P. aeruginosa Bacteremiaa
| Characteristics | Total N=69 |
Died N=42 |
Alive N=27 |
P-value | OR | 95% CI |
|---|---|---|---|---|---|---|
| Age (years), (mean, SD) | 64.6, 17.4 | 63.1, 16.7 | 66.8, 18.5 | 0.395 | ||
| Male gender, n (%) | 55 (79.7) | 35 (83.3) | 20 (74.1) | 0.351 | 1.750 | 0.536–5.712 |
| Underlying disease, n (%) | 68 (98.6) | 41 (97.6) | 27 (100.0) | 1.000 | 0.976 | 0.931–1.023 |
| Diabetes mellitus | 23 (33.3) | 14 (33.3) | 9 (33.3) | 1.000 | 1.000 | 0.359–2.789 |
| Chronic lung disease | 24 (34.8) | 18 (42.9) | 6 (22.2) | 0.079 | 2.625 | 0.879–7.838 |
| Chronic renal failure | 13 (18.8) | 11 (26.2) | 2 (7.4) | 0.103 | 4.435 | 0.899–21.884 |
| Solid organ cancer | 16 (23.2) | 7 (16.7) | 9 (33.3) | 0.109 | 0.400 | 0.128–1.250 |
| Cardiovascular disease | 45 (65.2) | 32 (76.2) | 13 (48.1) | 0.017 | 3.446 | 1.222–9.715 |
| Solid-organ transplantation | 3 (4.3) | 1 (2.4) | 2 (7.4) | 0.693 | 0.305 | 0.026–3.538 |
| Hematological Disease | 7 (10.1) | 4 (9.5) | 3 (11.1) | 1.000 | 0.842 | 0.173–4.096 |
| Benign biliary tract disease | 3 (4.3) | 0 (0.0) | 3 (11.1) | 0.056 | 1.125 | 0.985–1.285 |
| Primary site of infection, n (%) | ||||||
| Lung | 44 (63.8) | 32 (76.2) | 12 (44.4) | 0.007 | 4.000 | 1.415–11.310 |
| Soft-tissue | 1 (1.4) | 1 (2.4) | 0 (0.0) | 1.000 | 0.976 | 0.931–1.023 |
| Biliary tract | 4 (5.8) | 0 (0.0) | 4 (14.8) | 0.020 | 1.174 | 1.003–1.374 |
| Urinary tract | 1 (1.4) | 0 (0.0) | 1 (3.7) | 0.391 | 1.038 | 0.964–1.118 |
| Catheter-related | 4 (5.8) | 1 (2.4) | 3 (11.1) | 0.324 | 0.195 | 0.019–1.983 |
| Unknown | 15 (21.7) | 8 (19.0) | 7 (25.9) | 0.499 | 0.672 | 0.212–2.134 |
| Nosocomial infectionb, n (%) | 53 (76.8) | 33 (78.6) | 20 (74.1) | 0.666 | 1.283 | 0.413–3.985 |
| Comorbid condition, n (%) | ||||||
| Corticosteroid use | 18 (26.1) | 14 (33.3) | 4 (14.8) | 0.153 | 2.875 | 0.832–9.940 |
| Immune deficiencyc | 5 (7.2) | 5 (11.9) | 0 (0.0) | 0.148 | 0.881 | 0.788–0.985 |
| Neutropeniad | 7 (10.1) | 6 (14.3) | 1 (3.7) | 0.311 | 4.333 | 0.492–38.191 |
| Intravenous catheterization | 8 (11.6) | 3 (7.1) | 5 (18.5) | 0.291 | 0.338 | 0.074–1.553 |
| Blood transfusion | 23 (33.3) | 20 (47.6) | 3 (11.1) | 0.004 | 7.273 | 1.896–27.895 |
| Coinfection with other bacteria | 17 (24.6) | 13 (31.0) | 4 (14.8) | 0.218 | 2.578 | 0.741–8.971 |
| Antimicrobial therapy regimen, n (%) | 67 (97.1) | 42 (100.0) | 25 (92.6) | 0.150 | 1.080 | 0.971–1.202 |
| Monotherapye | 13 (18.8) | 5 (11.9) | 8 (29.6) | 0.066 | 0.321 | 0.092–1.117 |
| Combined antibiotic therapyf | 54 (78.3) | 37 (88.1) | 17 (63.0) | 0.014 | 4.353 | 1.288–14.707 |
| Resistance profile | ||||||
| CRPA | 40 (58.0) | 30 (71.4) | 10 (37.0) | 0.005 | 4.250 | 1.519–11.889 |
| MDRPA | 41 (59.4) | 29 (69.0) | 12 (44.4) | 0.042 | 2.788 | 1.024–7.596 |
| LOS (days), median (IQR) | 17.0 (10.8–27.3) |
12.5 (9.0–27.0) |
22.0 (14.0–33.5) | 0.184 | ||
| Received mechanical ventilation, n (%) | 33 (47.8) | 30 (71.4) | 3 (11.1) | <0.001 | 20.000 | 5.060–79.047 |
| Admitted to ICU, n (%) | 37 (53.6) | 34 (81.0) | 3 (11.1) | <0.001 | 34.000 | 8.168–141.520 |
Note: The definitions of aP. aeruginosa bacterium, bnosocomial infection, cimmune deficiency, dneutropenia, eantibiotic monotherapy and fcombination therapy are seen in the annotation of Table 1.
Abbreviations: SD, standard deviation; IQR, interquartile range; ICU, intensive care unit; LOS, length of hospital stay; CRPA, carbapenem-resistant P. aeruginosa; MDRPA, multidrug-resistant P. aeruginosa; OR, odds ratio; CI, confidence interval.